Pain treatment
AssigneeBenitec Biopharma Limited
InventorsPeter William French, Michael Wayne Graham
Life of this patent
Estimating the term…
Abstract
The disclosure relates to an RNA interference (RNAi) agent and the use of that RNAi agent to treat chronic pain in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The DNA-directed RNA interference (ddRNAi) agent for inhibiting expression of one or more target sequences in a pain associated gene comprises, one or more effector sequence sequences and effector complement sequences of at least 17 nucleotides in length, wherein the effector sequence is substantially complementary to the predicted transcript of a target sequence within a pain associated gene.
Claims25
A DNA-directed RNA interference (ddRNAi) agent for inhibiting expression of one or more target sequences in a pain associated gene, the ddRNAi agent comprising, in a 5′ to 3′ direction:
- an effector sequence set forth in SEQ ID NO:
- 23;
- and
- an effector complement sequence, wherein the effector complement sequence is substantially complementary to the effector sequence.
A DNA-directed RNA interference (ddRNAi) agent for inhibiting expression of one or more target sequences in a pain associated gene, the ddRNAi agent comprising, in a 5′ to 3′ direction:
- an effector sequence of at least 17 nucleotides in length;
- and
- an effector complement sequence, wherein the effector complement sequence is substantially complementary to the effector sequence;
- and
- wherein the effector sequence is substantially complementary to a predicted transcript of the target sequence set forth in SEQ ID NO:
- 5.
Dependencies are inferred from the claim text.